LifeSciences BC > News > Member Announcements > 2015 > Access to New Medicines in Public Drug Plans: Canada and Comparable Countries Report

Member Announcements

Access to New Medicines in Public Drug Plans: Canada and Comparable Countries Report

May 22, 2015 – Rx & D

Access to New Medicines in Public Drug Plans: Canada and Comparable Countries report
Canada’s Research-Based Pharmaceutical Companies (Rx&D) has just released the 2015 edition of the Access to New Medicines in Public Drug Plans: Canada and Comparable Countries report.   Previously known as the International Report on Access to Medicines (IRAM), the report is a continuation of yearly studies that began in 2006.
Rx&D commissioned IMS Brogan to conduct the study, significantly revamping the methodology and data sources to make the report more rigorous, comparable and open from previous years. Here is the link to the news release and the report:http://www.canadapharma.org/News.asp?a=view&id=118
Some key findings from the report include:
•      From Health Canada approval to a medicine’s reimbursement by a provincial drug plan takes over a year – about 462 days on average, across public provincial plans comprising 80% of the national public plan population.
•      In 2014, only 23% of 141 Health Canada-approved new medicines were included in public plans, ranking Canada 17 out of 18, compared to other OECD countries.
•      In Canada, 29% of cancer medicines were covered in public drug plans across provinces comprising at least 80% of the eligible national public drug plan population, ranking Canada in 16th place of 18 countries.
•      Canadian public drug plans placed reimbursement conditions on 90% of new medicines when measured across provinces comprising 80% of the eligible national public drug plan population.
•      In Canada, 20% of new biologic medicines were reimbursed in public drug plans across provinces comprising at least 80% of the eligible national public drug plan population, putting Canada in 17th place of 18 countries.

For more information or to discuss the Report please contact:
John Willow
Regional Director – BC
(based in Victoria, BC)
T: 250-995-2411
C: 250-589-5752
F: 613-236-6756
jwillow@canadapharma.org
55 rue Metcalfe Street, Suite/bureau 1220
Ottawa, ON K1P 6L5
www.canadapharma.org